2025
Mepolizumab in patients with severe asthma & BEC ≥150–<300 cells/µL: Benefits at 2 years
Canonica G, Bagnasco D, Lee J, Chupp G, Schleich F, Oppenheimer J, Zhang L, Alfonso-Cristancho R, Howarth P. Mepolizumab in patients with severe asthma & BEC ≥150–<300 cells/µL: Benefits at 2 years. ERJ Open Research 2025, 01390-2024. DOI: 10.1183/23120541.01390-2024.Peer-Reviewed Original ResearchClinically significant exacerbationsBlood eosinophil countMaintenance oral corticosteroidsSevere asthmaRate of clinically significant exacerbationsMedian average daily doseFEV 1Effect of mepolizumabInitiation of mepolizumabProportion of patientsObservational cohort studyReal-world effectivenessClinical trial evidenceForced expiratory volumePoor disease controlMepolizumab treatmentAverage daily doseOral corticosteroidsSingle-armACQ-5Daily doseSignificant exacerbationsEosinophil countMepolizumabCohort studyVariability in Long COVID Definitions and Validation of Published Prevalence Rates
Wisk L, L’Hommedieu M, Roldan K, Mannan I, Spatz E, Weinstein R, Venkatesh A, Gottlieb M, Huebinger R, Rising K, Montoy J, Stephens K, Rodriguez R, Hill M, O’Laughlin K, Gentile N, Idris A, Li S, Santangelo M, Kean E, McDonald S, Gatling K, Elmore J. Variability in Long COVID Definitions and Validation of Published Prevalence Rates. JAMA Network Open 2025, 8: e2526506. PMID: 40794409, DOI: 10.1001/jamanetworkopen.2025.26506.Peer-Reviewed Original ResearchConceptsSelf-reported long COVIDSARS-CoV-2 testingCohort studyPublished definitionsLong COVIDFollow-up surveyPrevalence of long COVIDPublished prevalence ratesOlder with symptomsInspiring participationNegative SARS-CoV-2 testCOVID prevalenceMonths postinfectionMain OutcomesClinical carePublished literatureSecondary outcomesPrevalence ratesCOVID-19 illnessCriterion standardMulticenter cohort studySARS-CoV-2ParticipantsPrevalenceLow-to-moderate sensitivityChanges in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide
Lu Y, Liu Y, Totojani T, Kim C, Khera R, Xu H, Brush J, Krumholz H, Abaluck J. Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide. JAMA Network Open 2025, 8: e2526013. PMID: 40779264, PMCID: PMC12334959, DOI: 10.1001/jamanetworkopen.2025.26013.Peer-Reviewed Original ResearchConceptsHealth care expendituresCardiovascular risk factorsCare expendituresCohort studyRisk factorsYale New Haven Health SystemCohort study of adultsType 2 diabetes statusLong-term impactStudy of adultsHealth systemRetrospective cohort studyBlood pressureHemoglobin A1c reductionMain OutcomesTotal cholesterolSentara HealthcareInpatient staySecondary outcomesGlucagon-like peptide-1 receptor agonistsPrimary outcomeHealthPeptide-1 receptor agonistsAssociated with clinical outcomesAssociated with reductionsLong-Term Services and Supports in Supplemental Benefits in Medicare Advantage Plans
Bhaumik D, Grabowski D. Long-Term Services and Supports in Supplemental Benefits in Medicare Advantage Plans. JAMA Network Open 2025, 8: e2526406. PMID: 40788644, DOI: 10.1001/jamanetworkopen.2025.26406.Peer-Reviewed Original ResearchConceptsMA beneficiariesMA plansHome-based palliative careSupplemental benefitsSupport servicesCohort studyIn-home supportive servicesMedicare AdvantageCenters for Medicare & Medicaid Services dataCaregiver support servicesAdult day servicesLongitudinal cohort studyHealth maintenance organizationMedicaid Services dataLong-term serviceMedicare Advantage plansNonopioid pain managementCounty levelPalliative careProvider organization plansMain OutcomesMaintenance organizationDay servicesPain managementLTSSTiming of repeat epinephrine to inform paediatric anaphylaxis observation periods: a retrospective cohort study
Dribin T, Sampson H, Zhang Y, Boyd S, Zhang N, Michelson K, Neuman M, Brousseau D, Mistry R, Freedman S, Aronson P, Bergmann K, Boswell B, Chinta S, Chua W, Cohen A, Cohen J, Daggett A, Davis J, Freeman J, Khanna K, Knoles C, Kwan K, Larsen C, Lee J, Lubell T, Metcalf A, Moake M, Nesiama J, Ngo T, Pulcini C, Russo C, Singh N, Srivastava G, Strutt J, Thapar V, Vander Wyst C, Walsh P, Wolnerman Y, Schnadower D, Academy of Pediatrics P, Kanngiesser A, McGarghan F, Dulchavsky A, Costalez J, DesPain A, Armanious M, Haghnazarian E, Brown-Whitehorn T, Weigert R, Dayan P, Meltzer J, Chowdhury N, Benedetti J, Sinziana C, Handorf A, Ruthford M, Devens M, Mecham C, Holland J, Casas T, Brown J, Panda P, Morrow A, Maready M, Nathani Y, Stevens M, Abraham G, Yen K, Cooper-Sood J, Woolf S. Timing of repeat epinephrine to inform paediatric anaphylaxis observation periods: a retrospective cohort study. The Lancet Child & Adolescent Health 2025, 9: 484-496. PMID: 40506197, DOI: 10.1016/s2352-4642(25)00139-7.Peer-Reviewed Original ResearchConceptsElectronic medical recordsEmergency departmentRetrospective cohort studyCohort studyMedical recordsDocumentation of symptomsCardiovascular involvementHealth-care facilitiesEpinephrine doseAcute allergic reactionsNational Institutes of HealthCumulative incidenceNational Center for Advancing Translational SciencesInstitutes of HealthChildren Aged 6 MonthsClinical ModificationHospital wardsIncidence rateICD-10Observation periodPrimary outcomeAllergic reactionsSecondary to medicationsInitiation to discontinuationKaplan-Meier analysisTiming of Disability Diagnosis and Accommodations During Medical School by First-Generation Status, Race, Ethnicity, and Gender.
Nguyen M, Green C, Mason H, Pereira-Lima K, Sheets Z, Schroth S, Smeltz L, Moreland C, Betchkal R, Growbowski C, Boatright D, Kim M, Meeks L. Timing of Disability Diagnosis and Accommodations During Medical School by First-Generation Status, Race, Ethnicity, and Gender. Academic Medicine 2025 PMID: 40550131, DOI: 10.1097/acm.0000000000006147.Peer-Reviewed Original ResearchMedical school matriculantsClinical accommodationsSchool matriculantsMedical studentsTime of diagnosisDisability diagnosisModified Poisson regressionAssociated with likelihoodPhases of medical trainingNo significant associationRetrospective cohort studyDiagnosis of disabilityPoisson regressionMedical trainingRelative riskDisability typeCohort studyRequesting accommodationsMedical schoolsSignificant associationGraduation statusAccommodation requestsDisabilityFirst-generation college graduatesTimely diagnosisAPOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban
Clocchiatti-Tuozzo S, Rivier C, Renedo D, Huo S, de Havenon A, Hawkes M, Gilmore E, Schwamm L, Sheth K, Gill T, Falcone G. APOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban. JAMA Neurology 2025, 82 PMID: 40549373, PMCID: PMC12186128, DOI: 10.1001/jamaneurol.2025.0182.Peer-Reviewed Original ResearchRisk of intracranial hemorrhagePopulation-based studyYears of follow-up dataApo E4Cox proportional hazards modelsAPOE e4 alleleIntracranial hemorrhageRisk prediction scoreCerebral amyloid angiopathyClinical decision-makingProportional hazards modelAtrial fibrillationIncreased risk of ICHMultivariate Cox proportional hazards modelMain OutcomesIncident intracranial hemorrhageEuropean ancestryCohort studyInclusion criteriaHistory of ischemic strokeAmyloid angiopathyE4 variantHazards modelIncreased riskE4 allelePrevalence and Phenotype of Food Allergy in Children with Cystic Fibrosis
Nguyen H, Shabanova V, McCollum S, Polk B, Lee T, Whittington K, Cunha P, Bruscia E, Egan M, Emmenegger M, Leeds S. Prevalence and Phenotype of Food Allergy in Children with Cystic Fibrosis. Annals Of Allergy Asthma & Immunology 2025 PMID: 40550267, DOI: 10.1016/j.anai.2025.06.024.Peer-Reviewed Original ResearchCystic fibrosisCF patientsFood allergyUS pediatric populationElectronic medical recordsPediatric populationPhenotypes of food allergyRetrospective pediatric cohort studyPrevalence of FAFA prevalenceCystic Fibrosis Foundation RegistryMale CF patientsUnited StatesPediatric CF patientsPancreatic enzyme replacementPediatric cohort studyIgE-mediated FACohort studyEstimated prevalenceInclusion criteriaMedical informationDevelopment of FAMedical recordsFA diagnosisPrevalenceAge, Race, and Ethnicity of Maternal Grandparents in Autism Spectrum Disorder, a California Multigenerational Study
Chow T, Meng Q, Xiao J, O'Sharkey K, Liew Z, Ritz B. Age, Race, and Ethnicity of Maternal Grandparents in Autism Spectrum Disorder, a California Multigenerational Study. Autism Research 2025 PMID: 40542519, DOI: 10.1002/aur.70074.Peer-Reviewed Original ResearchOdds ratioOlder grandparentsBirth cohort studyMother-child pairsHispanic grandmothersASD riskCohort studyInfluence of ageInverse associationWhite raceInvestigate associationsGrandparent ageYounger ageLogistic regressionOlder ageAutism spectrum disorderSpectrum disorderRace/ethnicityAgeOddsRiskMaternal grandparentsGrandparentsDisordersGrandmothersPrevalence of Hypertension in the Late Postpartum Period by Hypertensive Status in Pregnancy
Sinnott C, Culhane J, Lundsberg L, Partridge C, Denoble A. Prevalence of Hypertension in the Late Postpartum Period by Hypertensive Status in Pregnancy. O&G Open 2025, 2: e093. DOI: 10.1097/og9.0000000000000093.Peer-Reviewed Original ResearchElevated blood pressureLate postpartum periodBlood pressurePostpartum periodAcademic health care systemHypertension statusDelivery hospitalization dischargeWeeks of gestationRetrospective cohort studyHealth care systemNormal blood pressureDiastolic blood pressureElectronic medical recordsPrevalence of hypertensionSystolic blood pressureRates of hypertensionPostpartum hypertensionMm HgCare systemCohort studyMonths postpartumPregnancyLate postpartumPatient attributesMedical recordsUnderstanding Racial and Ethnic Disparities in Myasthenia Gravis Outcomes
McLaren N, Roy B, Nowak R. Understanding Racial and Ethnic Disparities in Myasthenia Gravis Outcomes. Neurology Clinical Practice 2025, 15: e200503. PMID: 40584640, PMCID: PMC12204767, DOI: 10.1212/cpj.0000000000200503.Peer-Reviewed Original ResearchLong-term outcomes of patientsOutcomes of patientsLong-term outcomesAA patientsNon-Hispanic patientsMyasthenia gravisWhite patientsHistory of thymomaLong-term outcome analysisRetrospective cohort studyYears of follow-up dataDiagnosis of MGRepetitive nerve stimulationFollow-up dataSingle-fiber electromyographyMG crisisClinical featuresClinical profileLogistic regression modelsEthnic differencesAntibody seropositivityCohort studyNerve stimulationOutcome analysisPatientsCost Disparities with Age in the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) in Ontario, Canada
Wang Y, Pond G, Gafni A, Kong C, Ellis P. Cost Disparities with Age in the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) in Ontario, Canada. Current Oncology 2025, 32: 346. PMID: 40558289, PMCID: PMC12191781, DOI: 10.3390/curroncol32060346.Peer-Reviewed Original ResearchConceptsCancer-attributable costsPhase of careNon-small-cell lung cancerAdvanced non-small-cell lung cancerInstitute for Clinical Evaluative SciencesHealthcare costsEnd-of-lifePre-diagnosis costsCost disparityEnd-of-life phaseDiagnosis of advanced non-small-cell lung cancerStage IV non-small-cell lung cancerTreatment of advanced non-small-cell lung cancerIV non-small-cell lung cancerRetrospective cohort studyLung cancerEvaluative SciencesPre-DiagnosisCancer diagnosisCohort studyOlder patientsDeceased patientsCareReceiving chemotherapyMedian ageLong-term, bidirectional associations between depressive symptom severity and opioid use among people with HIV: A prospective cohort study
Macmadu A, Li Y, Bhondoekhan F, Chang C, Bahji A, Crystal S, Gordon K, Kerns R, Vickers-Smith R, Edelman E, Marshall B. Long-term, bidirectional associations between depressive symptom severity and opioid use among people with HIV: A prospective cohort study. Addictive Behaviors Reports 2025, 22: 100619. PMID: 40547483, PMCID: PMC12182372, DOI: 10.1016/j.abrep.2025.100619.Peer-Reviewed Original ResearchDepressive symptom severityVeterans Aging Cohort StudySymptom severityOpioid useCohort studySubstance use disordersPrescription opioid useProspective cohort studyOpioid use disorderAging Cohort StudyMental health servicesDose-response patternGeneralized Estimating Equation modelsVeterans Health Administration sitesUse disorderClinical characteristicsProspective cohortBidirectional associationsFollow-upStudy entryOpioidHarm reduction servicesBidirectional relationshipPLHIVAdministration siteAssociation of Primary Language with Treatment and Outcomes in Inflammatory Bowel Disease.
Sahyoun L, Chavez V, Vasudevan J, Kogan L, Mukkamala B, Ochi M, Anand T, Ahmed Z, Tang Z, Feagins L, Gaidos J. Association of Primary Language with Treatment and Outcomes in Inflammatory Bowel Disease. Clinical And Translational Gastroenterology 2025 PMID: 40478247, DOI: 10.14309/ctg.0000000000000868.Peer-Reviewed Original ResearchCorticosteroid-free clinical remissionInflammatory bowel diseaseAdvanced therapiesClinical remissionDisease activityCohort study of adult patientsBowel diseaseStudy of adult patientsElevated fecal calprotectinBaseline disease activityPhysician global assessmentIBD disease activityRates of inflammatory bowel diseaseFecal calprotectinAdult patientsTherapy useCohort studyPrimary outcomeMultivariate analysisSecondary outcomesMulti-centerClinic visitsDisease outcomePatientsBaseline differencesRisk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study.
Morales D, Bu F, Viernes B, DuVall S, Matheny M, Simon K, Falconer T, Richter L, Ostropolets A, Lau W, Man K, Chattopadhyay S, Mathioudakis N, Minty E, Nishimura A, Sun F, Yin C, Seager S, Chai Y, Zhou J, Lu Y, Reyes C, Pistillo A, Duarte-Salles T, Blacketer C, Schuemie M, Ryan P, Krumholz H, Hripcsak G, Khera R, Suchard M. Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care 2025 PMID: 40465422, DOI: 10.2337/dc25-0154.Peer-Reviewed Original ResearchRisk of thyroid tumorThyroid tumorsGLP-1RADPP-4isHazard ratioThyroid malignancyCohort studyIncreased riskSodium-glucose cotransporter 2 inhibitorsElectronic health record databaseGlucagon-like peptide 1 receptor agonistsEstimate hazard ratiosRandom-effects meta-analysisGLP-1 receptor agonistsPeptide 1 receptor agonistsDipeptidyl peptidase 4 inhibitorsThyroid tumor incidenceUsers of SGLT2isHealth record databaseSecond-line treatmentType 2 diabetes mellitusNew-user cohort studyRetrospective cohort studyUsers of sulfonylureasIntention-to-treatEffect modification by cardiovascular and metabolic disease onset on long-term PM2.5 exposure and mortality: a nationwide cohort study
Jang H, Park J, Lee E, Kang D, Moon J, Song I, Ahn S, Kim A, Kang C, Oh J, Kwon D, Min J, Kim E, Bell M, Kim H, Lee W. Effect modification by cardiovascular and metabolic disease onset on long-term PM2.5 exposure and mortality: a nationwide cohort study. Scientific Reports 2025, 15: 19570. PMID: 40467860, PMCID: PMC12137577, DOI: 10.1038/s41598-025-04498-z.Peer-Reviewed Original ResearchConceptsLong-term PM2.5 exposureEffect modificationPM2.5 exposureEstimate effect modificationPM2.5-mortality associationsPopulation-representative cohortTarget specific interventionsMyocardial infarctionNationwide cohort studyNon-accidental deathsEffects of PM2.5PM2.5-mortalityRisk of PM2.5Preemptive careCox regression modelsHTN/DMCohort studyHazard ratioDisease onsetCerebrovascular diseaseRegression modelsMetabolic disease onsetCohortRenal diseaseMortalityBiomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer. JAMA Network Open 2025, 8: e2514519. PMID: 40493365, PMCID: PMC12152704, DOI: 10.1001/jamanetworkopen.2025.14519.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerEGFR variationPD-L1ALK rearrangementCell lung cancerDriver alterationsMedical costsLung cancerCohort studyProgrammed cell death 1 ligand 1Cell death 1 ligand 1Biomarker statusMedian overall survivalRetrospective cohort studyLower medical costsOverall survivalTargeted therapyNon-smallPatient cohortMonthly medical costsFollow-upStudy cohortBiomarker testingAssociated with higher costsPublic Water Arsenic and Birth Outcomes in the Environmental Influences on Child Health Outcomes Cohort
Nigra A, Bloomquist T, Rajeev T, Burjak M, Casey J, Goin D, Herbstman J, Ornelas Van Horne Y, Wylie B, Cerna-Turoff I, Braun J, McArthur K, Karagas M, Ames J, Sherris A, Bulka C, Padula A, Howe C, Fry R, Eaves L, Breton C, Cassidy-Bushrow A, Lewis J, MacKenzie D, Beene D, Farzan S, Sathyanarayana S, Hipwell A, Morello-Frosch R, Snyder B, Hartert T, Elliott A, O’Connor T, Kress A, Smith P, Newby L, Adair L, Jacobson L, Catellier D, McGrath M, Douglas C, Duggal P, Knapp E, Kress A, Blackwell C, Mansolf M, Lai J, Ho E, Cella D, Gershon R, Macy M, Das S, Freedman J, Mallal S, McLean J, Shah R, Shilts M, Alshawabkeh A, Cordero J, Meeker J, Trasande L, Camargo C, Hasegawa K, Zhu Z, Sullivan A, Dabelea D, Perng W, Bekelman T, Wilkening G, Magzamen S, Moore B, Starling A, Rinehart D, Koinis Mitchell D, D'Sa V, Deoni S, Mueller H, Duarte C, Monk C, Canino G, Posner J, Murray T, Lugo-Candelas C, Dunlop A, Brennan P, Hockett C, Elliott A, Ferrara A, Croen L, Hedderson M, Ainsworth J, Bacharier L, Bendixsen C, Gern J, Gold D, Hartert T, Jackson D, Johnson C, Joseph C, Kattan M, Khurana Hershey G, Lemanske, Jr. R, Lynch S, Miller R, O’Connor G, Ober C, Ownby D, Rivera-Spoljaric K, Ryan P, Seroogy C, Singh A, Wood R, Zoratti E, Habre R, Farzan S, Gilliland F, Hertz-Picciotto I, Bennett D, Schweitzer J, Schmidt R, LaSalle J, Hipwell A, Karr C, Bush N, LeWinn K, Sathyanarayana S, Zhao Q, Tylavsky F, Carroll K, Loftus C, Leve L, Ganiban J, Neiderhiser J, Weiss S, Litonjua A, McEvoy C, Spindel E, Tepper R, Newschaffer C, Lyall K, Volk H, Landa R, Ozonoff S, Piven J, Hazlett H, Pandey J, Schultz R, Dager S, Botteron K, Messinger D, Stone W, Ames J, O'Connor T, Miller R, Oken E, Hacker M, James-Todd T, O'Shea T, Fry R, Frazier J, Singh R, Rollins C, Montgomery A, Vaidya R, Joseph R, Washburn L, Gogcu S, Bear K, Rollins J, Hooper S, Taylor G, Jackson W, Thompson A, Daniels J, Hernandez M, Lu K, Msall M, Lenski M, Obeid R, Pastyrnak S, Jensen E, Sakai C, Santos H, Kerver J, Paneth N, Barone C, Elliott M, Ruden D, Fussman C, Herbstman J, Margolis A, Schantz S, Geiger S, Aguiar A, Tabb K, Strakovsky R, Woodruff T, Morello-Frosch R, Padula A, Stanford J, Porucznik C, Giardino A, Wright R, Wright R, Collett B, Baumann-Blackmore N, Gangnon R, McKennan C, Wilson J, Altman M, Aschner J, Stroustrup A, Merhar S, Moore P, Pryhuber G, Hudak M, Reynolds Lyndaker A, Lampland A, Rochelson B, Jan S, Blitz M, Katzow M, Brown Z, Chiuzan C, Rafael T, Lewis D, Meirowitz N, Poindexter B, Gebretsadik T, Osmundson S, Straughen J, Eapen A, Cassidy-Bushrow A, Wegienka G, Sitarik A, Woodcroft K, Urquhart A, Levin A, Johnson-Hooper T, Davidson B, Ma T, Barrett E, Blaser M, Dominguez-Bello M, Horton D, Jimenez M, Rosen T, Palomares K, Avalos L, Zhu Y, Hunt K, Newman R, Bloom M, Alkis M, Roberts J, Mumford S, Burris H, DeMauro S, Yee L, Hamvas A, Olidipo A, Haddad A, Eiland L, Spillane N, Suri K, Fisher S, Goldstein J, Mithal L, DeRegnier R, Maitre N, Nguyen R, JaKa M, Sidebottom A, Paidas M, Potter J, Ruby N, Duthely L, Jayakumar A, Young K, Maldonado I, Miller M, Slaughter J, Keim S, Lynch C, Venkatesh K, Whitworth K, Symanski E, Northrup T, Mendez-Figueroa H, Mosquera R, Karagas M, Madan J, MacKenzie D, Lewis J, Rennie B, Leventhal B, Kim Y, Bishop S, Nozadi S, Luo L, Lester B, Marsit C, Everson T, Loncar C, McGowan E, Sheinkopf S, Carter B, Check J, Helderman J, Neal C, Smith L. Public Water Arsenic and Birth Outcomes in the Environmental Influences on Child Health Outcomes Cohort. JAMA Network Open 2025, 8: e2514084. PMID: 40522663, PMCID: PMC12171937, DOI: 10.1001/jamanetworkopen.2025.14084.Peer-Reviewed Original ResearchConceptsBirth weight-for-gestational age z-scoreLow birth weightAge z-scoreAdjusted risk ratiosAdverse birth outcomesBirth outcomesBirth weightMaximum contaminant levelWater arsenicWater arsenic exposureRisk ratioGestational agePreterm birthZ-scoreContamination levelsCohort studyAssociated with adverse birth outcomesHigher risk of low birth weightArsenic exposureParent-infant dyadsRisk of low birth weightUS Environmental Protection Agency maximum contaminant levelChild health outcomesAssociated with birth outcomesEnvironmental Protection Agency maximum contaminant levelP-450 Two for the Price of One: Twins and Multiple Births Following a Natural vs. Programmed Single Frozen Blastocyst Transfer Cycle
Meyers A, Mensah V, Morse B, Sakkas D, Vaughan D. P-450 Two for the Price of One: Twins and Multiple Births Following a Natural vs. Programmed Single Frozen Blastocyst Transfer Cycle. Human Reproduction 2025, 40: deaf097.756. DOI: 10.1093/humrep/deaf097.756.Peer-Reviewed Original ResearchFrozen embryo transferMultiple pregnanciesHigher-order multiplesEmbryo transferNatural frozen embryo transferRisk of monozygotic twinningRisk of multiple pregnancyNatural cycle groupPregnancy outcome dataRetrospective cohort studyElectronic medical record databaseNatural cyclesLikelihood of pregnancySingleton pregnanciesMedical record databaseTwin pregnanciesChi-square testFetal sacMethods PatientsOvulated oocytesUnassisted conceptionWider implicationsCohort studyPregnancyTheoretical riskEvaluating palliative care needs of early-phase clinical trial patients.
Crowley F, Zeng L, Hobensack M, Lehrman S, Afezolli D, Kelly L, Wey W, Chen J, Austin V, Easton E, Pagala A, Wu K, Lucas N, Wilk J, Marron T, Smith C, Gelfman L, Doroshow D. Evaluating palliative care needs of early-phase clinical trial patients. Journal Of Clinical Oncology 2025, 43: 12086-12086. DOI: 10.1200/jco.2025.43.16_suppl.12086.Peer-Reviewed Original ResearchPalliative careEnd-of-lifeEarly phase clinical trialsOutpatient PCReferral systemPalliative care needsSpecialty palliative careCancer type distributionPC servicesCare needsRetrospective cohort studyEvaluate demographic characteristicsPrevalent symptomsRate of constipationPC guidelinesPhysical discomfortCohort studyIncrease accessFisher's exact testPhase clinical trialsClinical trial patientsDemographic characteristicsMann-Whitney U testChi-squareCategorical variables
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply